Compound Electrolyte Glucose Injection-M3B
Function and Efficacy
In rabbits within 4 days of surgical invasion, the electrolytes (Na, K, C1) were maintained in a good balance from the first to the fourth day after surgery by intravenous drip of 50ml/kg/day. In addition, blood pH, PC02, and H2CO3 also returned to preoperative values on the fifth day after surgery, and plasma non-protein nitrogen (NPN) concentration also dropped to preoperative values on the third day after surgery, so it is an effective postoperative maintenance fluid.
Ingredients
This product is a compound preparation, and its composition is: each 500ml bottle contains 0.875g sodium chloride, 0.75g potassium chloride, 1.12g sodium lactate, and 13.50g glucose.
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| Sodium chlorideIngredients |
Maintain electrolyte balance, regulate blood pH and postoperative recovery More |
7647-14-5 | 43 | |
| Potassium chlorideIngredients |
Maintain electrolyte balance, regulate blood pH and postoperative recovery More |
7447-40-7 | 38 | |
| Sodium lactateIngredients |
Maintain electrolyte balance, regulate blood pH and postoperative recovery More |
312-85-6 | 0 | |
| GLUCOSEIngredients |
Maintain electrolyte balance, regulate blood pH and postoperative recovery More |
58367-01-4 | 14 |
Appearance
This product is a colorless or almost colorless clear liquid.
Indication
Fluid and electrolyte replenisher. Replenishes and maintains fluids and electrolytes when oral intake is impossible or insufficient.
Usage and Dosage
For adults, 500ml~1000ml intravenous drip at a time. The administration rate is 300ml~500ml per hour (about 80~130 drops per minute); for children, 50ml~100ml per hour, and the dosage can be increased or decreased appropriately according to age, symptoms and weight.
Adverse Reactions
When large amounts of the drug are administered rapidly, pulmonary edema, cerebral edema, peripheral edema, water intoxication, and hyperkalemia may occur.
Precautions
1. Hyperlactatemia; 2. Patients with hyperkalemia, oliguria, Addison's disease, severe burns, and hyperazotemia; 3. Patients with renal insufficiency without hyperkalemia; 4. Patients with heart failure; 5. Patients with severe liver failure; 6. Patients with decreased urine volume due to obstructive urinary tract disease; 7. Patients with diabetes.
Drug Interactions
Not yet clear.
Storage
Keep tightly closed.
Packaging Specification
500ml
Manufacturer
Guangdong Otsuka Pharmaceutical Co., Ltd.
-
Founded in:
1993-06-01 -
Address:
Foshan Shunde District Ronggui Street High-tech Industrial Development Park -
Tax NO.:
91440606617475057M -
Registered Funds:
$28.4 million -
Website:
-
Email: